imdatifan (NKT2152)

P1/2, N=518, Recruiting, Hoffmann-La Roche | Trial completion date: Dec 2027 --> Sep 2027 | Trial primary completion date: Dec 2027 --> Jul 2027

By expanding upon the foundation established by belzutifan, the field is poised for further therapeutic advances.

P1/2, N=518, Recruiting, Hoffmann-La Roche | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Dec 2027

Moreover, treatment with NKT2152 significantly reduced tumor growth in both cell line-derived and patient-derived xenograft models. In conclusion, our findings provide novel insights into the prognostic and functional role of HIF2A in ovarian CCC and underscore its potential as a promising therapeutic target.

P1/2, N=139, Recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting

Consistent with these observations, two different allosteric HIF2 inhibitors, belzutifan and NKT2152, rapidly ameliorated hypercalcemia and cachexia in patients with ccRCC, including in some who did not exhibit objective tumor shrinkage. Our findings support prospective clinical studies to determine whether HIF2 inhibitors can be leveraged not only for tumor control, but also for the treatment of cancer-associated cachexia in renal cell carcinoma.

P1/2, N=139, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.

P1/2, N=120, Terminated, NiKang Therapeutics, Inc. | Trial completion date: Sep 2026 --> Sep 2025 | Active, not recruiting --> Terminated | Trial primary completion date: May 2025 --> Aug 2025; This study was terminated as a result of Sponsor portfolio reprioritization.

P2, N=18, Terminated, NiKang Therapeutics, Inc. | N=172 --> 18 | Trial completion date: Jun 2026 --> Sep 2025 | Active, not recruiting --> Terminated; This study was terminated as a result of Sponsor portfolio reprioritization.

Further, we show that the increased PTHLH expression is both necessary and sufficient for the induction of hypercalcemia and cachexia in preclinical orthotopic cell line tumor models. Consistent with these observations, two different allosteric HIF2 inhibitors, belzutifan and NKT2152, rapidly ameliorated hypercalcemia and cachexia in ccRCC patients, including in some patients who did not exhibit objective tumor shrinkage.

P1/2, N=104, Recruiting, Jiangsu Hansoh Pharmaceutical Co., Ltd.

We discuss the major key inhibitors, with focus on belzutifan and review the various trials investigating its efficacy in monotherapy as well as in combination therapies in RCC...We also highlight emerging HIF-2α inhibitors currently in clinical trials, namely casdatifan, NKT-2152, and DFF332. Finally, we address the major toxicities and management of these inhibitors.